Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Human endogenous retrovirus onco-exaptation counters cancer cell senescence through calbindin
Jan Attig, … , Charles Swanton, George Kassiotis
Jan Attig, … , Charles Swanton, George Kassiotis
Published May 16, 2023
Citation Information: J Clin Invest. 2023;133(14):e164397. https://doi.org/10.1172/JCI164397.
View: Text | PDF
Research Article Genetics Oncology

Human endogenous retrovirus onco-exaptation counters cancer cell senescence through calbindin

  • Text
  • PDF
Abstract

Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterize most cancer types and are linked with disease outcomes. However, the underlying processes are incompletely understood. Here, we show that elevated transcription of HERVH proviruses predicted survival of lung squamous cell carcinoma (LUSC) and identified an isoform of CALB1, encoding calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1 expression was initiated in preinvasive lesions and associated with their progression. Calbindin loss in LUSC cell lines impaired in vitro and in vivo growth and triggered senescence, consistent with a protumor effect. However, calbindin also directly controlled the senescence-associated secretory phenotype (SASP), marked by secretion of CXCL8 and other neutrophil chemoattractants. In established carcinomas, CALB1-negative cancer cells became the dominant source of CXCL8, correlating with neutrophil infiltration and worse prognosis. Thus, HERVH-CALB1 expression in LUSC may display antagonistic pleiotropy, whereby the benefits of escaping senescence early during cancer initiation and clonal competition were offset by the prevention of SASP and protumor inflammation at later stages.

Authors

Jan Attig, Judith Pape, Laura Doglio, Anastasiya Kazachenka, Eleonora Ottina, George R. Young, Katey S.S. Enfield, Iker Valle Aramburu, Kevin W. Ng, Nikhil Faulkner, William Bolland, Venizelos Papayannopoulos, Charles Swanton, George Kassiotis

×

Figure 5

Lack of HERVH-CALB1 expression associates with cellular senescence.

Options: View larger image (or click on image) Download as PowerPoint
Lack of HERVH-CALB1 expression associates with cellular senescence.
(A) ...
(A) UMAP clustering of HARA cells, calbindin-deficient HARA 3D5 cells, HARA.LTR7-GFP+ cells, and HARA.LTR7-GFP– cells according to scRNA-Seq profiling, labeled by their genotype/phenotype (left) or by their assigned cluster (right). (B) Heatmap of expression of 566 genes differentially expressed (≥2-fold, q < 0.05) between HARA 3D5 cell clusters (clusters 9–11) and all other cell clusters from A (left), and functional annotation by GO of the upregulated and downregulated genes in this comparison (right). P values calculated with the g:SCS algorithm. (C) Heatmap of expression of selected genes upregulated in HARA 3D5 cell clusters, ordered by fold change in expression in the cell clusters from A. (D) Normalized expression of CXCL8, CXCL1, SPANXD, and MT2A in UMAP cell cluster projections as in A. (E) γH2AX and phalloidin staining of HARA and HARA 3D5 cells (left). Lower panels show magnified images of the indicated regions in the upper panels. Scale bars: 20 μm. Percentage of γH2AX + cells, additionally exhibiting signs of DNA damage, in the same preparations (right). Symbols represent individual regions of interest. (F) Mean CXCL8 concentration (±SEM) over time in the supernatants of HARA and HARA 3D5 cells, determined by ELISA (P = 6 per time point). P value calculated with Student’s t test. One representative of 3 independent experiments is shown.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts